SEC Form 4 · accession 0001171843-17-001506
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian Mortimer
Officer — CFO & COO
Period of report
Mar 13, 2017
Accepted (ET)
Mar 14, 2017 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.40 | Mar 13, 2017 | A | 75,000 | A | — | Mar 12, 2027 | Common Shares | 75,000 | 75,000 | D |
Explanation of responses
- F1Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.